<!– Name:DistributionId Value:8835803 –>
<!– Name:EnableQuoteCarouselOnPnr Value:False –>
<!– Name:IcbCode Value: –>
<!– Name:CustomerId Value:1214936 –>
<!– Name:HasMediaSnippet Value:false –>
<!– Name:AnalyticsTrackingId Value:78509552-a016-44dd-9a01-762dab27a0de –>
VANCOUVER, British Columbia, May 10, 2023 — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (âOptimiâ or the âCompanyâ), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (âMDMAâ), natural GMP-grade psilocybin, along with natural health product formulations, is pleased to announce the receipt of its Natural Health Product Site Licence following an assessment by the Natural and Non-prescription Health Products Directorate.
Under section 29 of the Natural Health Products Regulations, the expanded licensing allows for the manufacturing, packaging, and labelling of Natural Health Products (âNHPsâ) at the Companyâs Princeton, British Columbia facility.
Further, the licence also gives Optimi the ability to encapsulate products on site.
âThis expands our ability to produce our products on site for global market distribution,â said Optimi CEO, Bill Ciprick. âThis licence enables the Company to further diversify and leverage the potential of its existing manufacturing, processing and packaging capabilities to streamline fulfilment and reduce costs across its supply chain to support continued growth.â
Todayâs announcement affirms Optimiâs commitment to supplying large scale research and development programs through its 10,000 square foot GMP compliant manufacturing facility.
For more information or to arrange an interview, please contact Michael Kydd at:
investors@optimihealth.ca
902.880.6121
www.optimihealth.ca
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)
Optimi Health Corp. an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (âMDMAâ), natural GMP-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Companyâs goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimiâs products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.
FORWARDâLOOKING STATEMENTS
This news release contains forwardâlooking statements and forwardâlooking information within the meaning of Canadian securities legislation (collectively, âforwardâlooking statementsâ) that relate to Optimiâs current expectations and views of future events, including the ability of the Company to perform its obligations under the supply contract, to achieve the objectives of the founders and the timing of the Q2 2023 earnings. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as âwill likely result,â âare expected to,â âexpects,â âwill continue,â âis anticipated,â âanticipates,â âbelieves,â âestimated,â âintends,â âplans,â âforecast,â âprojection,â âstrategy,â âobjective,â and âoutlookâ) are not historical facts and may be forwardâlooking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forwardâlooking statements. No assurance can be given that these expectations will prove to be correct and such forwardâlooking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forwardâlooking statements pertaining to activities proposed to be conducted under the Companyâs approved Health Canada dealerâs licence and associated business related to Psilocybin, Psilocin, other psychedelic substances, some being synthetically formulated, and Optimiâs plans, focus and objectives.
Forwardâlooking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimiâs control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forwardâlooking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVIDâ19 pandemic and other factors set forth under âForwardâLooking Statementsâ and âRisk Factorsâ in the Companyâs Annual Information Form dated January 9, 2023, and other continuous disclosure filings available under Optimiâs profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forwardâlooking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forwardâlooking statement.
Any forwardâlooking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.